

**Notice of References Cited**

Application/Control No.

10/551,405

Applicant(s)/Patent Under

Reexamination

BERZOFSKY ET AL.

Examiner

Jeffrey S. Parkin

Art Unit

1648

Page 1 of 1

**U.S. PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A US-6,133,418	10-2000	Bolognesi et al.	530/324
	B US-			
	C US-			
	D US-			
	E US-			
	F US-			
	G US-			
	H US-			
	I US-			
	J US-			
	K US-			
	L US-			
	M US-			

**FOREIGN PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N				
	O				
	P				
	Q				
	R				
	S				
	T				

**NON-PATENT DOCUMENTS**

*	Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
U	Sarobe, P., et al., 1998, Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement as secondary HLA-A2.1 binding positions, J. Clin. Invest. 102:1239-1248.
V	Berzofsky, J. A., et al., 1999, Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections, Immunol. Rev. 170:151-172.
W	Berzofsky, J. A., et al., Strategies for designing and optimizing new generation vaccines, Nat. Rev. Immunol. 1:209-219.
X	Herrer, E., et al., 1996, Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor, J. Infect. Dis. 173:476-479.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a))  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.